| Q37308576 | A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment. |
| Q38839768 | A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes. |
| Q37700992 | Assessing the subcellular distribution of oncogenic phosphoinositide 3-kinase using microinjection into live cells |
| Q91889015 | Autoinhibition in Ras effectors Raf, PI3Kα, and RASSF5: a comprehensive review underscoring the challenges in pharmacological intervention |
| Q45961245 | Biochemical and biological characterization of tumor-associated mutations of p110alpha. |
| Q37234005 | Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care. |
| Q39210209 | Comparative proteomic analysis implicates eEF2 as a novel target of PI3Kγ in the MDA-MB-231 metastatic breast cancer cell line |
| Q39645865 | Comparison of intracellular signalling by insulin and the hypermitogenic AspB10 analogue in MCF‐7 breast adenocarcinoma cells |
| Q37109227 | Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. |
| Q36674615 | Cytoprotective signaling associated with nitric oxide upregulation in tumor cells subjected to photodynamic therapy-like oxidative stress |
| Q36425968 | Development of novel therapeutic strategies that target HIF-1. |
| Q38159756 | Differential modulation of apoptotic processes by proanthocyanidins as a dietary strategy for delaying chronic pathologies. |
| Q39952263 | Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha |
| Q42918632 | Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket |
| Q28588322 | Dixdc1 is a critical regulator of DISC1 and embryonic cortical development |
| Q91675504 | Does Ras Activate Raf and PI3K Allosterically? |
| Q24304940 | Down-regulation of ubiquitin ligase Cbl induced by twist haploinsufficiency in Saethre-Chotzen syndrome results in increased PI3K/Akt signaling and osteoblast proliferation |
| Q43579660 | Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas. |
| Q40170788 | Exploring the specificity of the PI3K family inhibitor LY294002. |
| Q46226492 | Expression and purification of PI3 kinase alpha and development of an ATP depletion and an alphascreen PI3 kinase activity assay |
| Q35127176 | G-protein alpha-s and -12 subunits are involved in androgen-stimulated PI3K activation and androgen receptor transactivation in prostate cancer cells. |
| Q37313157 | Hepatic vitamin A preloading reduces colorectal cancer metastatic multiplicity in a mouse xenograft model |
| Q34152723 | Individual and combined soy isoflavones exert differential effects on metastatic cancer progression |
| Q37140410 | Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha |
| Q27646654 | Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit |
| Q36778676 | Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies. |
| Q37250634 | Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. |
| Q79817234 | Myeloproliferative disorders: premalignant, stem cell, G1 diseases? |
| Q42948871 | Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signaling and thrombus formation. |
| Q38785807 | Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion. |
| Q36958575 | Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas |
| Q33680436 | Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85alpha, p55alpha, and p50alpha |
| Q38943885 | Phosphatidylinositol 3-kinase mediates the ability of retinol to decrease colorectal cancer cell invasion |
| Q34203861 | Phosphatidylinositol 3-kinase: the oncoprotein |
| Q38684394 | Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas. |
| Q34410971 | Phosphoinositide 3-kinase controls early and late events in mammalian cell division |
| Q37205526 | Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death |
| Q36461618 | Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. |
| Q37340915 | Phosphoinositide 3-kinases in cell migration |
| Q36398266 | Post-transcriptional regulation in cancer progression : Microenvironmental control of alternative splicing and translation |
| Q37872280 | Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases |
| Q40063828 | Quantitative measurement of phosphatidylinositol 3,4,5-trisphosphate |
| Q34625262 | Rapid upregulation of cytoprotective nitric oxide in breast tumor cells subjected to a photodynamic therapy-like oxidative challenge |
| Q35720258 | Rare cancer-specific mutations in PIK3CA show gain of function |
| Q27025414 | Regulation of platelet plug formation by phosphoinositide metabolism |
| Q54497681 | Sinonasal mucosal melanoma: Molecular profile and therapeutic implications from a series of 32 cases. |
| Q42923599 | Synthesis, structural elucidation and DNA-dependant protein kinase and antiplatelet studies of 2-amino-[5, 6, 7, 8-mono and 7, 8-di-substituted]-1,3-benzoxazines |
| Q36313171 | The Akt of translational control |
| Q64275651 | The mechanism of PI3Kα activation at the atomic level |
| Q37454384 | The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. |
| Q34096861 | The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells |
| Q38723074 | Thyroid Hormone Controls Breast Cancer Cell Movement via Integrin αV/β3/SRC/FAK/PI3-Kinases. |
| Q35048673 | Treatment with insulin analog X10 and IGF-1 increases growth of colon cancer allografts |
| Q34250032 | c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment |
| Q36623679 | mTOR, translation initiation and cancer |